ASTA Comments to FDA on Voluntary Sesame Labeling Guidance
ASTA issued comments to the Food and Drug Administration (FDA) in February 2021 on the Voluntary Disclosure of Sesame as an Allergen: Guidance for Industry. Comments outline inconsistencies and confusion arising from the guidance, including that FDA policy already provides that sesame should not be labeled under the generic declaration of spices. ASTA requests that FDA revoke the voluntary guidance due to the legislative process and the FASTER Act.
Membership Required
A valid ASTA membership is required to access this page. Please use the form below to log in with your ASTA member account.
Log in
Not a member yet? Click here to learn about joining ASTA today.
Related Resources
ASTA Comments to FDA on Allergen Thresholds
ASTA issued comments to the Food and Drug Administration (FDA) in May 2013 regarding allergen thresholds, advocating for FDA's role to protect public health and the food supply by adopting allergen policies based on sound science and thoughtful policy.
ASTA Comments to FDA on Sesame Allergens
ASTA issued comments to the Food and Drug Administration (FDA) in December 2018 in response to the FDA's Request for Comment on Sesame as an Allergen in Foods. The comments support labeling sesame as a major allergen, provided that sufficient time is offered to implement new labeling and GMP requirements.
